文献速递肝病消化道肿瘤与早癌

全国范围内肝细胞癌降期等待名单结局的经验:所有纳入者中高脱落率

National Experience on Waitlist Outcomes for Down-Staging of Hepatocellular Carcinoma: High Dropout Rate in All-Comers.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-08-28

该回顾性分析基于UNOS数据库2010至2019年23,398例肝细胞癌MELD例外申请患者,比较始终符合米兰标准、符合UNOS降期标准及超出UNOS降期标准(所有纳入者)三组的等待名单脱落情况。2年累积脱落概率分别为米兰组19%、UNOS降期组25%(P < .001)、所有纳入者降期组30%(P < .001)。所有纳入者中甲胎蛋白大于100 ng/mL亚组的2年脱落概率为52%,其他超出米兰标准者为26%(P < .001)。

要点

  • 所有纳入者降期组2年脱落概率30%,高于UNOS降期组25%和米兰组19%。
  • 降期组多因素分析中,甲胎蛋白21-100、101-1000、大于1000 ng/mL的脱落风险HR分别为1.63、2.06、4.58。
  • 所有纳入者中甲胎蛋白大于100 ng/mL亚组2年脱落概率52%,其他超出米兰标准者为26%。

核心结论

  • 所有纳入者降期组在初始成功降期至米兰标准后,等待名单脱落风险显著高于UNOS降期组和米兰组。
  • 所有纳入者降期组中甲胎蛋白大于100 ng/mL亚组未来2年脱落概率大于50%。
  • 这些观察提示扩大降期指征时失败可能性高。

研究设计与样本

  • 回顾性分析UNOS数据库2010至2019年提交肝细胞癌MELD例外申请的23,398例等待肝移植患者。
  • 分为始终符合米兰标准组(n = 20,579)、UNOS降期组(n = 2151)和所有纳入者降期组(n = 668)。

主要发现

  • 2年累积脱落概率:米兰组19%,UNOS降期组25%(P < .001),所有纳入者降期组30%(P < .001)。
  • 降期组多因素分析中,列入等待名单时MELD预测脱落(HR 1.06;P < .001),初始总肿瘤直径预测脱落(HR 1.04;P = .002)。
  • 以甲胎蛋白≤20 ng/mL为参照,21-100、101-1000和大于1000 ng/mL的脱落风险HR分别为1.63、2.06和4.58(P < .001)。
  • 所有纳入者中甲胎蛋白大于100 ng/mL亚组2年脱落概率52%,其他超出米兰标准者为26%(P < .001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The United Network for Organ Sharing (UNOS) grants priority listing for liver transplant for patients with hepatocellular carcinoma after successful down-staging to Milan criteria. We evaluated the national experience on down-staging by comparing 2 down-staging groups: tumor burden meeting UNOS down-staging (UNOS-DS) inclusion criteria, and all-comers (AC)-DS with initial tumor burden beyond UNOS-DS criteria vs patients always within Milan criteria. METHODS: We performed a retrospective analysis of the UNOS database of 23,398 patients listed for liver transplant who had submitted a hepatocellular carcinoma Model for End-Stage Liver Disease exception application from 2010 to 2019, classified as always within Milan (n = 20,579), UNOS-DS (n = 2151), and AC-DS (n = 668). RESULTS: The 2-year cumulative probabilities of dropout were 19% for Milan, 25% for UNOS-DS (P < .001), and 30% for AC-DS (P < .001). In multivariate analysis of the down-staging groups, factors predicting dropout included Model for End-Stage Liver Disease at listing (hazard ratio [HR], 1.06; P < .001) and initial total tumor diameter (HR, 1.04; P = .002). Compared with α-fetoprotein (AFP) level ≤20 ng/mL, AFP levels of 21 to 100, 101 to 1000, and greater than 1000 ng/mL were associated with a higher risk of dropout (HRs, 1.63, 2.06, and 4.58, respectively; P < .001). A subset of all-comers with AFP levels greater than 100 ng/mL had a 2-year probability of dropout of 52% vs 26% for all others beyond Milan criteria (P < .001). CONCLUSIONS: All-comers had a significantly higher risk for waitlist dropout compared with the UNOS-DS and Milan groups after initial successful down-staging to Milan criteria. In particular, the subgroup of AC-DS with an AFP level greater than 100 ng/mL had a greater than 50% probability of dropout in the next 2 years. These observations suggest a high likelihood of failure when expanding the indications for down-staging.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Huang AC, Dodge JL, Yao FY, et al. National Experience on Waitlist Outcomes for Down-Staging of Hepatocellular Carcinoma: High Dropout Rate in All-Comers. Clin Gastroenterol Hepatol. 2022. PMID: 36038129. doi:10.1016/j.cgh.2022.08.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。